AGTC to Participate in Upcoming Investor Conferences
BTIG Biotechnology Conference– New York( August 8, 2022) Jon Lieber, Chief Financial Officer, will participate in one-on-one investor meetings. Wedbush PacGrow Healthcare Conference– Virtual ( August 9, 2022) Sue Washer, President and Chief Executive Officer, and Mr. Lieberwill participate in one-on-one investor meetings. H.C. Wainwright2nd Annual Ophthalmology Conference– Virtual ( August 17, 2022)
A presentation with
Ms. Washerwill be available to view on-demand beginning on Wednesday, August 17at 7:00 a.m. ETthrough the entirety of the conference.
The presentation can be accessed by visiting http://ir.agtc.com/events-and-presentations. Replays will be available on the Company's website following the events.
AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is designing and constructing critical gene therapy elements and bringing them together to develop customized therapies with the potential to address unmet patient needs. AGTC’s most advanced clinical programs in XLRP and ACHM CNGB3 leverage its technology platform to potentially improve vision for patients with inherited retinal diseases. Its preclinical programs build on the AGTC’s AAV manufacturing technology and scientific expertise. AGTC is advancing multiple pipeline candidates to address substantial unmet clinical needs in optogenetics, otology and CNS disorders, and has entered into strategic collaborations with companies including
T: (212) 867-1768
Chief Financial Officer
T: (617) 843-5778
Source: Applied Genetic Technologies Corporation